The final, formatted version of the article will be published soon.
REVIEW article
Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1485532
Progress in immunotherapy for brain metastatic melanoma
Provisionally accepted
Shicheng Zheng
1
Zhongqiao Lin
2*
Ruibo Zhang
1*
ZiHang Cheng
1*
KaiXin Li
1*
ChenKai Gu
1*
Yu Chen
2*
Jing Lin
2*- 1 Fujian Medical University, Fuzhou, China
- 2 Fujian Provincial Cancer Hospital, Fuzhou, Fujian Province, China
Melanoma is highly aggressive, with brain metastasis being a significant contributor to poor outcomes. Immunotherapy has emerged as a crucial treatment modality for melanoma, particularly for addressing brain metastases. This review explores recent developments in immunotherapy for patients with melanoma brain metastasis, with such treatments encompassing immune checkpoint inhibitors and various immunotherapy combination approaches, such as dual immunotherapy, immunotherapy combined with chemotherapy, immunotherapy combined with targeted drugs, and immunotherapy combined with radiotherapy. This article also discusses existing treatment obstacles and potential future avenues for research and clinical practice.
Keywords: Melanoma, brain metastases, Immunotherapy, immune checkpoint inhibitors, combination therapy
Received: 28 Aug 2024; Accepted: 07 Nov 2024.
Copyright: © 2024 Zheng, Lin, Zhang, Cheng, Li, Gu, Chen and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Zhongqiao Lin, Fujian Provincial Cancer Hospital, Fuzhou, Fujian Province, China
Ruibo Zhang, Fujian Medical University, Fuzhou, China
ZiHang Cheng, Fujian Medical University, Fuzhou, China
KaiXin Li, Fujian Medical University, Fuzhou, China
ChenKai Gu, Fujian Medical University, Fuzhou, China
Yu Chen, Fujian Provincial Cancer Hospital, Fuzhou, Fujian Province, China
Jing Lin, Fujian Provincial Cancer Hospital, Fuzhou, Fujian Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.